Pasithea Therapeutics Corp(KTTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.58 | Insider Own | 3.59% | Shs Outstand | 33.4M | Perf Week | -8.78% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 39.47% | Insider Trans | 9.09% | Shs Float | 32.2M | Perf Month | -22.93% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -0.21 | Inst Own | 60.32% | Short Float | 0.84% | Perf Quarter | -12.61% |
| Income | -0.02B | P/S | - | EPS this Y | 73.88% | Inst Trans | 1.25% | Short Ratio | 1.14 | Perf Half Y | -43.98% |
| Sales | 0.00B | P/B | 0.3 | EPS next 5Y | 42.61% | ROA | -61.97% | Short Interest | 0.27M | Perf YTD | -65.35% |
| Book/sh | 1.49 | P/C | 0.33 | EPS past 3/5Y | 35.92% -117.71% | ROE | -65.49% | 52W High | -78.3% ($2.06) | Perf Year | -45.65% |
| Cash/sh | 1.37 | P/FCF | - | Sales past 3/5Y | - | ROIC | -42.72% | 52W Low | 59.07% ($0.28) | Perf 3Y | -94.45% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 79.07% | Gross Margin | - | Volatility(W/M) | 7.3% 7.14% | Perf 5Y | -99.13% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 26.25 | EPS Q/Q | 75.06% | Profit Margin | - | RSI (14) | 33.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 26.25 | Sales Q/Q | - | SMA20 | -11.05% ($0.51) | Beta | 0.36 | Target Price | $3 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -11.53% ($0.51) | Rel Volume | 0.27 | Prev Close | $0.45 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -35.3% ($0.7) | Avg Volume(3M) | 0.24M | Price | $0.45 |
| IPO | 2021/9/15 | Option/Short | No/Yes | Trades | 202 | Volume | 64,433 | Change | -1.74% |
🧬 Pasithea Therapeutics () is a clinical-stage biotech developing PAS-004, a next-generation macrocyclic MEK inhibitor, as its lead pipeline candidate. The company primarily targets RASopathies and MAPK pathway-driven tumors, simultaneously running a Phase 1 trial for advanced solid tumors and a Phase 1/1b trial for plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1), while also securing FDA Fast Track designation.
Over the past 1 year, on the lower side
78% below its 1-year high.
Traded less than usual That is 27% of its average volume.
KTTA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +73.9% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.1%. The S&P 500 did +79% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 60.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF 0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #483 of 592 in the industry
Based on market cap of $15M.
KTTA#483 Pasithea Therapeutics Corp $15M PER - 
KPTI#484 Karyopharm Therapeutics Inc $15M PER - 
AKTX#485 Akari Therapeutics Plc ADR $15M PER - 
HIND#486 Vyome Holdings Inc $14M PER - 
AEON#487 AEON Biopharma Inc $14M PER - 
FAQ
What kind of company is KTTA?
KTTA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KTTA?
The market cap of KTTA is approximately $15M, ranking 5,362 within its sector.
What is the 52-week high and low for KTTA?
KTTA has recorded a 52-week high of $2.06 and a low of $0.28.
